Ma Fenlian, Zhang Qian, Zheng Lishu
National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Yingxin Street 100, Beijing, 100052, China,
Biotechnol Lett. 2015 Apr;37(4):773-7. doi: 10.1007/s10529-014-1739-3. Epub 2014 Dec 4.
Mucosal immunity may provide a defense against human papillomavirus (HPV) but there are no FDA-approved adjuvants capable of stimulating immune responses within mucosal tissues. After mice were immunized intranasally three times with HPV16 L1 virus-like particles plus with JY adjuvant, which is composed of interleukin-2 and chitosan, sera IgG antibody titer, sera neutralizing antibody titer, sIgA concentration in respiratory tract washes, sIgA concentration in vaginal washes and the number of spot-forming cells (SFC) in splenic lymphocytes were 320 ± 15, 40 ± 2, 27 ± 1.3, 27 ± 1.7 μg/ml and 176.7 ± 6 SFC/10(6), respectively; In the group without JY adjuvant, the outcomes were 80 ± 9.4, null, 22 ± 1, 20 ± 2.4 μg/ml and 91 ± 5.2 SFC/10(6), respectively. Therefore, JY adjuvant may be an effective mucosal adjuvant for HPV vaccine in mice.
黏膜免疫可能提供针对人乳头瘤病毒（HPV）的防御，但尚无美国食品药品监督管理局（FDA）批准的能够刺激黏膜组织内免疫反应的佐剂。在用HPV16 L1病毒样颗粒加由白细胞介素-2和壳聚糖组成的JY佐剂对小鼠进行三次鼻内免疫后，血清IgG抗体滴度、血清中和抗体滴度、呼吸道冲洗液中的分泌型IgA（sIgA）浓度、阴道冲洗液中的sIgA浓度以及脾淋巴细胞中的斑点形成细胞（SFC）数量分别为320±15、40±2、27±1.3、27±1.7μg/ml和176.7±6 SFC/10(6)；在无JY佐剂的组中，结果分别为80±9.4、无、22±1、20±2.4μg/ml和91±5.2 SFC/10(6)。因此，JY佐剂可能是小鼠HPV疫苗的一种有效黏膜佐剂。
